OncoBlast-Best of Hematology and Breast Cancer II
This CME-accredited activity, Best of Hematology and Breast Cancer II, is designed to offer practical insights into hematology and breast cancer care by educating clinicians involved in cancer care. This activity is designed to provide physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other healthcare professionals with the latest updates in the field. It will highlight a multidisciplinary approach and the integration of new advances in patient-centered care of breast cancer.
OncoBlast-Targeted Therapy in Breast Cancer: Integrating Precision Oncology Into Real-World Clinical Practice
This interactive module equips clinicians with practical strategies to apply precision oncology in breast cancer care, focusing on biomarker-driven treatment decisions across various clinical scenarios.
OncoBlast-Updates in Low-Grade and Aggressive Lymphomas
Updates in Low-Grade and Aggressive Lymphomas is a CME-accredited OncoBlast activity designed to help oncology professionals apply the latest advances in lymphoma care through interactive, case-based learning. Using clinical scenarios and knowledge checks, learners will review current standards and emerging therapies for both indolent and aggressive lymphomas, including antibody-drug conjugates, bispecific antibodies, BTK and BCL2 inhibitors, and CAR T-cell therapy. This microlearning activity emphasizes a multidisciplinary, patient-centered approach, equipping participants to integrate new evidence into real-world decision-making, recognize therapy-specific toxicities, and optimize treatment outcomes across diverse patient populations.
OncoBlast-Clinical Decisions in Lymphoid Cancers: Real-World Case Insights
This CME-accredited OncoBlast activity uses case-based questions to explore evolving treatment strategies in B-cell lymphomas, CLL, and Hodgkin lymphoma. Each interactive scenario is grounded in current clinical trials and guideline updates for practical, evidence-based learning.
OncoBlast-Personalized Lung Cancer Care: Updates on Efficacy, Toxicity, and Clinical Decision-Making
This CME-accredited OncoBlast activity uses gamified, case-based questions to reinforce key updates in the management of advanced non-small cell lung cancer (NSCLC). Topics include biomarker-driven therapies (EGFR, ALK, MET, BRAF, KRAS, HER2), treatment sequencing, and toxicity management. Learners will apply evidence-based strategies to real-world scenarios and stay current with the latest approvals and guidelines in precision oncology.
OncoBlast-Biomarkers & Immunotherapy in Precision Oncology
This gamified, CME-accredited OncoBlast activity immerses learners in the evolving landscape of molecular oncology. Through interactive challenges, participants will identify common molecular abnormalities across multiple cancer types, interpret biomarker results, and apply next-generation sequencing data to guide personalized treatment strategies. The course also explores emerging targeted therapies, testing methodologies, and the clinical impact of novel agents in development—equipping clinicians with the tools to deliver precision cancer care.
OncoBlast-Precision Oncology in GI Cancer: Integrating Biomarkers Into Clinical Practice
This CME-accredited OncoBlast activity uses case-based, ABIM-style questions to reinforce evidence-based clinical decision-making in gastrointestinal cancers. Participants will explore key advances in treatment selection and sequencing, biomarker-driven therapy, and evolving standards of care in GI malignancies. The interactive format is designed to challenge clinicians to synthesize clinical data, patient factors, and guideline recommendations in real-world scenarios.
OncoBlast-Advances in Lymphoma: Evidence-Based Decision-Making in Diagnosis and Treatment
This CME-accredited OncoBlast activity engages learners through a series of interactive, case-based questions covering the diagnosis, surveillance, prognostic markers, and evolving therapeutic strategies in Hodgkin and non-Hodgkin lymphomas. Participants will apply current clinical guidelines and emerging data to real-world decision-making, with a focus on personalized treatment selection, biomarker-driven therapy, and novel agents such as bispecific antibodies and targeted treatments.
OncoBlast-Navigating Multiple Myeloma Therapy: Toxicity, Timing, and Treatment Choice
This interactive, case-based OncoBlast activity equips oncology professionals with practical strategies for optimizing treatment decisions in multiple myeloma. Participants will apply evidence-based guidelines to manage toxicities, select appropriate therapies based on patient- and disease-specific factors, and understand the evolving role of bispecific antibodies, CAR-T therapy, and maintenance regimens in clinical practice.
OncoBlast-GU Oncology II
This CME-accredited activity, GU Oncology 2, is designed to improve the care of GU patients by educating clinicians involved in cancer care. This activity is designed to provide physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other healthcare professionals with the latest updates in the field. It will highlight a multidisciplinary approach and the integration of new advances in patient-centered care of GU Cancers
OncoBlast-Advances in GI Cancer Care: Case-Based Approaches to Modern Therapy
This OncoBlast activity uses clinical cases to explore new standards in treating gastroesophageal, colorectal, biliary, and neuroendocrine cancers. Learners will apply recent trial data to make evidence-based decisions in both curative and metastatic settings.
OncoBlast-Best of Hematology and Breast Cancer I
This CME-accredited activity, Best of Hematology and Breast Cancer I, is designed to offer practical insights into hematology and breast cancer care by educating clinicians involved in cancer care. This activity is designed to provide physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other healthcare professionals with the latest updates in the field. It will highlight a multidisciplinary approach and the integration of new advances in patient-centered care of breast cancer.
OncoBlast-Precision Oncology in GU Cancers: Biomarkers, Sequencing, and Toxicity Management
This CME-accredited OncoBlast activity offers an interactive, case-based learning experience focused on genitourinary (GU) cancers. Through real-world clinical scenarios, learners will engage with evolving standards of care in GU malignancies. Emphasis is placed on biomarker-guided therapies, sequencing of systemic treatments, management of treatment-related toxicities, and applying evidence-based decision-making in complex clinical settings.
OncoBlast-Targeted and Systemic Therapies in Advanced Sarcoma: A Case-Based Learning Module
This CME-accredited activity explores the evolving treatment landscape of advanced and metastatic soft tissue sarcomas through high-yield clinical cases. Using interactive questions and evidence-based rationales, participants will enhance their ability to make therapeutic decisions involving chemotherapy, targeted therapy, immunotherapy, and surgical considerations across a spectrum of sarcoma subtypes.
OncoBlast-Thoracic Oncology Updates from ASCO 2025
The therapeutic landscape of thoracic oncology has changed dramatically over the past several years. The implementation of molecular testing has expanded treatment options for non-small cell lung cancers in both the curative and palliative-intent settings. Novel therapeutics are also making their way into the small cell lung cancer treatment paradigm improving outcomes for this disease that has historically had poor outcomes. This activity will help learners understand the various aspects of treatments in both NSCLC and SCLC, understand treatment indications for select biomarker-driven NSCLC, and appreciate nuances of therapy in NSCLC, SCLC, mesothelioma, and thymic tumors.
Oncoblast-Personalizing NSCLC Treatment: Biomarkers and Targeted Options II
This interactive, case-based OncoBlast activity helps clinicians navigate treatment decisions in NSCLC using molecular testing, targeted therapies, and immunotherapy. Through ABIM-style questions and expert explanations, learners will explore optimal diagnostic and treatment approaches based on actionable biomarkers.
OncoBlast-Personalizing NSCLC Treatment: Biomarkers and Targeted Options I
This interactive, case-based OncoBlast activity helps clinicians navigate treatment decisions in NSCLC using molecular testing, targeted therapies, and immunotherapy. Through ABIM-style questions and expert explanations, learners will explore optimal diagnostic and treatment approaches based on actionable biomarkers.
OncoBlast-Precision Oncology in GU Malignancies: Applying Biomarkers to Clinical Practice
This CME-accredited, case-based activity is designed to enhance clinical decision-making through the application of current evidence and best practices in GU oncology. Learners will engage with interactive scenarios that emphasize personalized treatment approaches, safe use of emerging therapies, and effective management of treatment-related toxicities.
OncoBlast-Optimizing Immuno-Oncology: Innovations in Immune Checkpoint Inhibitor Delivery
This accredited OncoBlast activity “Optimizing Immuno-Oncology: Innovations in Immune Checkpoint Inhibitor Delivery” is designed to engage learners through interactive, case-based challenges focused on evolving strategies for administering immune checkpoint inhibitors (ICIs). Covering both intravenous (IV) and subcutaneous (SC) delivery methods across multiple tumor types, this activity equips oncology care providers with practical tools to evaluate delivery options, manage adverse events, and integrate SC ICI approaches into real-world practice.
OncoBlast-GI Oncology Highlights from ASCO 2025: Practice-Changing Trials You Need to Know
This CME-accredited Oncoblast activity is designed to rapidly disseminate key updates in gastrointestinal (GI) oncology from the 2025 ASCO Annual Meeting. Through clinical scenarios and evidence-based insights, participants will review emerging data with implications for standard care across colorectal, gastric, hepatobiliary, and pancreatic cancers.
OncoBlast-Navigating the Shift: New NCCN Guidelines and Emerging Therapies in First-line mUC and MIBC
This CME-accredited OncoBlast activity delivers key updates on first-line treatment of metastatic urothelial carcinoma (mUC) and muscle-invasive bladder cancer (MIBC), including the latest guidelines and the emerging role of antibody-drug conjugates (ADCs). Through gamified, interactive case scenarios, participants will explore guideline-based care, optimal treatment sequencing, and strategies for managing adverse events. This activity supports the real-world application of evolving evidence in urothelial cancer management.
OncoBlast-Managing Multiple Myeloma: Case-Based Clinical Decisions
This CME-accredited OncoBlast activity uses case-based scenarios to guide oncology professionals through the diagnosis and management of smoldering and symptomatic multiple myeloma. Learners will review risk stratification, treatment selection, and emerging evidence on induction, maintenance, and supportive care strategies.
OncoBlast-Managing CAR T and Bispecific Therapies: A Case-Based Review
This CME-accredited OncoBlast course uses interactive cases to review the selection, toxicity management, and supportive care strategies for patients receiving CAR T-cell and bispecific antibody therapies. Learners will apply evidence-based approaches aligned with current guidelines.
OncoBlast-Frontline and Relapsed Management in B-Cell Lymphomas: What the Data Says
This CME-accredited OncoBlast course provides a case-based review of contemporary management strategies for B-cell non-Hodgkin lymphomas. Through real-world clinical scenarios, learners will explore when to initiate treatment, how to interpret landmark trial data, and best practices for integrating targeted therapies and maintenance approaches into personalized care.
OncoBlast-Malignant Hematology: MDS, AML, MPN and ALL
This CME-accredited activity, Malignant Hematology, is designed to enhance the knowledge and clinical competence of healthcare professionals involved in the care of patients with malignant hematologic disorders. The course will focus on acute myeloid leukemia (AML), its precursor conditions such as myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs), as well as acute lymphoblastic leukemia (ALL). Participants will receive up-to-date, evidence-based insights into diagnostic and therapeutic advances, with an emphasis on a multidisciplinary, patient-centered approach. This activity is intended for physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other healthcare providers involved in the management of hematologic malignancies.
OncoBlast-Multiple Myeloma
This CME-accredited activity, Multiple Myeloma, is designed to improve the care of Multiple patients by educating clinicians involved in cancer care. This activity is designed to provide physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other healthcare professionals with the latest updates in the field. It will highlight a multidisciplinary approach and the integration of new advances in patient-centered care of myeloma.
OncoBlast-Gynecologic Oncology - Updates from ASCO 2025
This CME-accredited activity, Gynecologic Oncology at Best of ASCO, is designed to improve the care of gynecologic cancer patients by educating clinicians involved in cancer care. This activity is designed to provide physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other healthcare professionals with the latest updates in the field. It will highlight a multidisciplinary approach and the integration of new advances in patient-centered care of breast cancer.
OncoBlast-Breast Cancer Updates
This CME-accredited activity is designed to improve the care of patients with breast cancer by educating health care professionals involved in their cancer care. This activity is designed to provide physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other healthcare professionals with the latest updates in the field. It highlights a multidisciplinary approach and focuses on new developments in the care of patients with breast cancer.